Preparation and characterization of a new class of polymeric ligand exchangers for selective removal of trace contaminants from water

2004 ◽  
Vol 60 ◽  
pp. 109-120 ◽  
Author(s):  
Wade D Henry ◽  
Dongye Zhao ◽  
Arup K SenGupta ◽  
Cliff Lange
2014 ◽  
Vol 85 ◽  
pp. 45-53 ◽  
Author(s):  
Byungryul An ◽  
Ka-Young Jung ◽  
Dongye Zhao ◽  
Sang-Hyup Lee ◽  
Jae-Woo Choi

2020 ◽  
Vol 20 (7) ◽  
pp. 490-500 ◽  
Author(s):  
Justin S. Becker ◽  
Amir T. Fathi

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2- hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause changes in genome structure and gene activity, culminating in an arrest of normal myeloid differentiation. These discoveries have motivated the development of a new class of selective small molecules with the ability to inhibit the mutant IDH enzymes while sparing normal cellular metabolism. These agents have shown promising anti-leukemic activity in animal models and early clinical trials, and are now entering Phase 3 study. This review will focus on the growing preclinical and clinical data evaluating IDH inhibitors for the treatment of IDH-mutated AML. These data suggest that inducing cellular differentiation is central to the mechanism of clinical efficacy for IDH inhibitors, while also mediating toxicity for patients who experience IDH Differentiation Syndrome. Ongoing trials are studying the efficacy of IDH inhibitors in combination with other AML therapies, both to evaluate potential synergistic combinations as well as to identify the appropriate place for IDH inhibitors within existing standard-of-care regimens.


1996 ◽  
Vol 33 (10-11) ◽  
pp. 139-147 ◽  
Author(s):  
Dongye Zhao ◽  
Arup K. Sengupta

This paper reports salient features of a new fixed-bed sorption process in regard to ultimate removal and recovery of phosphate from municipal and industrial wastewater. The sorbent, referred to as polymeric ligand exchanger(PLE), is essentially a copper(II) loaded specialty chelating polymer. Laboratory experiments have demonstrated that the PLE: can remove phosphate selectively from municipal and synthetic wastewater; is amenable to efficient regeneration; and provides opportunities to recover phosphate and reuse the spent regenerant for multiple numbers of cycles.


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Lyudmila P. Trenozhnikova ◽  
Almagul K. Khasenova ◽  
Assya S. Balgimbaeva ◽  
Galina B. Fedorova ◽  
Genrikh S. Katrukha ◽  
...  

We describe the actinomycete strain IMV-70 isolated from the soils of Kazakhstan, which produces potent antibiotics with high levels of antibacterial activity. After the research of its morphological, chemotaxonomic, and cultural characteristics, the strain with potential to be developed further as a novel class of antibiotics with chemotherapeutics potential was identified asStreptomycessp. IMV-70. In the process of fermentation, the strainStreptomycesspp. IMV-70 produces the antibiotic no. 70, which was isolated from the culture broth by extraction with organic solvents. Antibiotic compound no. 70 was purified and separated into individual components by HPLC, TLC, and column chromatography methods. The main component of the compound is the antibiotic 70-A, which was found to be identical to the peptolide etamycin A. Two other antibiotics 70-B and 70-C have never been described and therefore are new antibiotics. The physical-chemical and biological characteristics of these preparations were described and further researched. Determination of the optimal growth conditions to cultivate actinomycete-producer strain IMV-70 and development of methods to isolate, purify, and accumulate preparations of the new antibiotic no. 70 enable us to research further the potential of this new class of antibiotics.


1998 ◽  
Vol 07 (04) ◽  
pp. 503-508 ◽  
Author(s):  
ANDRZEJ SZCZEPAŃSKI

We shall present a new class of examples of high dimensional knot groups. All of them are HNN extensions of the Fibonacci groups. We give also some characterization of these groups.


Virology ◽  
1975 ◽  
Vol 64 (1) ◽  
pp. 144-152 ◽  
Author(s):  
Richard E. Depew ◽  
Thomas J. Snopek ◽  
Nicholas R. Cozzarelli
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document